Please login to the form below
autoimmune disease
This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
At the time the biotech said it would focus on potential therapies for cancer and autoimmune conditions, with its operations supported by GSK’s drug discovery capabilities. ... Last year, Lilly announced a $650m partnership with US biotech ImmuNext in
Latest news
-
FDA clears wider use for Boehringer’s Ofev in lung disease
rare autoimmune disease that affects around 100, 000 people in the US. ... The new label applies to between 18% and 32% of patients with around 200 separate disorders, including “unclassifiable ILDs, autoimmune ILDs, chronic hypersensitivity
-
Takeda buys coeliac disease partner PvP Biologics after phase 1 win
Coeliac disease is a common autoimmune condition characterised by inflammation of the small intestine, causing diarrhoea, abdominal pain and bloating, as well as impairing the ability to absorb nutrients from the ... TAK-062 is a highly targeted therapy
-
CRISPR gene-editing in cancer patients is safe, according to new study
This in turn helps to prevent autoimmune disease, while also preventing the immune system from killing cancer cells. ... Both have severe haemoglobinopathies – including transfusion-dependant beta thalassaemia (TDT) and severe sickle cell disease (SCD).
-
FDA approves Horizon's thyroid eye disease drug ahead of schedule
Tepezza is the first medicine approved in the rare autoimmune disease, which can cause eye bulging, facial disfigurement and vision loss. ... We believe teprotumumab may impact underlying mechanisms of fibrosis and could demonstrate utility beyond
-
Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial
Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... PNH). The head-to-head PEGASUS study
More from news
Approximately 4 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 2)
ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.
-
Managing medication non-adherence
Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to
-
Reaching new heights
Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020
-
Pharma deals during May 2014
Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of
-
The distressing impact of rare diseases
The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease
-
Akari Therapeutics strengthens board
His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop
-
David Horn Solomon takes the helm of Akari Therapeutics
biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.
-
Caldan Therapeutics appoints CEO
Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca
-
Santhera CEO Klaus Schollmeier joins SuppreMol
In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
PANDAS/PANS Awareness: A parent’s story
parent of a son recently diagnosed with PANDAS (paediatric autoimmune neuropsychiatric disorder associated with Streptococcus)…. ... As PANDAS is an autoimmune disease that leads to inflammation in the basal ganglia region of the brain, the symptoms
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
THE OTHER SIDE OF… CROHN’S DISEASE
Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... She believes that they follow a “by-the-book” mentality, not
More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
